David Bradlee, DO
Endocrinology, Diabetes & Metabolism · Bloomfield Hills, MINPI 1790731693
Payments from drug & device makers
Across 185 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$510
- Medtronic$422
- Novo Nordisk$376
- Amneal Pharmaceuticals LLC$225
- Lilly USA, LLC$216
- Abbott$201
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,23499%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 23 | $510 |
| Medtronic | 17 | $422 |
| Novo Nordisk | 21 | $376 |
| Amneal Pharmaceuticals LLC | 14 | $225 |
| Lilly USA, LLC | 14 | $216 |
| Abbott | 11 | $201 |
| AstraZeneca | 10 | $168 |
| AbbVie | 10 | $156 |
| Sanofi-aventis U.S. LLC | 7 | $128 |
| Amgen(2 entities) | 6 | $93 |
| Mannkind Corporation | 6 | $89 |
| Amryt Pharma Holdings Ltd | 5 | $84 |
| IBSA Pharma Inc. | 5 | $76 |
| Xeris Pharmaceuticals, Inc. | 5 | $71 |
| Dexcom, Inc. | 3 | $50 |
| Alvogen Inc | 3 | $49 |
| Johnson & Johnson | 3 | $41 |
| Cequr Corporation | 3 | $33 |
| Merck | 2 | $26 |
| Tandem Diabetes Care, Inc. | 2 | $24 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| BETA Bionics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Bayer | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Insulet Corporation | 1 | $13 |
| Senseonics, Incorporated | 2 | $12 |
| BD | 1 | $12 |
| Lifescan, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$130
- Korlym$115
How this compares
$3,266 in reported general payments places this provider in the 55th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $131,828 |
| TrulicityDulaglutide | 29 | $44,422 |
| JardianceEmpagliflozin | 24 | $31,606 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 113 | $18,012 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $17,300 |
| FarxigaDapagliflozin Propanediol | 12 | $16,919 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $12,934 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $12,637 |
| SynthroidLevothyroxine Sodium | 114 | $10,356 |
| Novolog FlexpenInsulin Aspart | 45 | $9,544 |
| NovologInsulin Aspart | 38 | $8,920 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $8,685 |
| Levemir FlexpenInsulin Detemir | 12 | $5,609 |
| HumalogInsulin Lispro | 18 | $5,478 |
| Levothyroxine Sodium | 401 | $4,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $376 | $140,748107 claims |
| Lilly USA, LLCTrulicity, Humalog | $216 | $49,90047 claims |
| Boehringer IngelheimJardiance | $17 | $31,60624 claims |
| AstraZenecaFarxiga | $168 | $16,91912 claims |
| AbbVieSynthroid | $156 | $10,356114 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $225 | $4,780401 claims |
| Sanofi-aventis U.S. LLCLantus | $128 | $2,20211 claims |
| PfizerLevoxyl | $14 | $11413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Bloomfield Hills
- George GrunbergerBloomfield Hills$1.9M
- Anjana MyneniBloomfield Hills$14K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.